Unlocking the potential of engineered immune cell therapy for solid tumors by Víctor Albarrán-Fernández, Laura Angelats, Julio Delgado, Alena Gros, Álvaro Urbano-Ispizua, Sònia Guedan, Aleix Prat

Get full text

Utility of Plasmapheresis in Autoimmune-Mediated Encephalopathy in Children: Potentials and Challenges by Abdulhafeez M. Khair

“…It is very crucial to consider early use of first-line immunotherapy modalities, save those children’s lives and improve outcomes. …”
Get full text

Update on the Treatment of Metastatic Urothelial Carcinoma by Nedal Bukhari, Humaid O. Al-Shamsi, Faisal Azam

“…In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy. This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.…”
Get full text

New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies by Ping Wang, Aitor Aguirre

“…Despite significant advances in recent years, such as the introduction of targeted therapies such as receptor tyrosine kinase inhibitors and immunotherapy, current approaches are insufficient to stop the advance of the disease and many cancer types remain largely intractable. …”
Get full text

Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes by Juan P. Cata, Claudius Conrad, Katy Rezvani

“…Several studies have demonstrated that it is associated with poor survival owing to cancer progression. Immunotherapy, especially NK cell transfer therapy, is an attractive alternative because current methodologies to isolate, generate, and expand NK cells have shown good safety profiles in current active investigations. …”
Get full text

KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis by Marc Otero-Mateo, Francesc Estrany Jr, Sabrina Arcas-Márquez, Laura Moya-Borrego, Giancarlo Castellano, Miquel Castany, Ramon Alemany, Cristina Fillat

Get full text

Clinical features of autonomic dysfunction in children with anti-N-methyl-D aspartic receptor encephalitis by Dongqing Li, Jing Sun, Guannan Li, Shuo Miao, Jian Yang, Jianzhao Zhang

“…Active initiation of second-line and long-term immunotherapy is recommended.…”
Get full text

Alpha-1 Antitrypsin as a Regulatory Protease Inhibitor Modulating Inflammation and Shaping the Tumor Microenvironment in Cancer by Siyu Xiang, Liu Yang, Yun He, Feng Ding, Shuangying Qiao, Zonghua Su, Zheng Chen, Aiping Lu, Fangfei Li

“…This review seeks to bridge the gap in the understanding of AAT between inflammatory diseases and cancer, and to foster deeper investigations into its translational potential in cancer immunotherapy in the future.…”
Get full text

Seven Immune-Related Genes’ Prognostic Value and Correlation with Treatment Outcome in Head and Neck Squamous Cell Carcinoma by Rui Mu, Yuehong Shen, Chuanbin Guo, Xinyun Zhang, Hongyu Yang, Huijun Yang

“…The low-risk HNSCC subjects might benefit from immunotherapy and chemotherapy.…”
Get full text

High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT) by Yuxuan Ding, Yong Feng, Yangfan Ye, Jiayi Shen, Chang Guo, Xia He, Liangjun Zhu, Lijun Wang

“…IntroductionMicrosatellite stable (MSS) colorectal cancer with liver metastases (CLRM) responds poorly to immunotherapy, and various approaches to break immune tolerance have been tried. …”
Get full text

GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma by Gabriela Piñón-Zárate, Miguel Ángel Herrera-Enríquez, Beatriz Hernández-Téllez, Katia Jarquín-Yáñez, Andrés Eliú Castell-Rodríguez

“…These results highlight the properties of GK-1 as an immunostimulant of DCs and suggest as a potential candidate the use of this immunotherapy against cancer disease.…”
Get full text

Neoadjuvant adebrelimab combined with chemotherapy (cisplatin/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS) by Yan Zhang, Qian Huang, Mengxia Li, Xi Zheng, Yanyang Liu, Long Tian, Guizhi Chen, Hongyu Xu, Daxing Zhu

“…However, the use of neoadjuvant immunotherapy in limited-stage SCLC is unknown but promising. …”
Get full text

Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival by Yin Leung, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Tony Shu‐Kam Mok, Henry Lik‐Yuen Chan, Stephen Lam Chan, Rashid Nok‐Shun Lui

“…ABSTRACT Purpose Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1‐antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunotherapy. Therefore, we retrospectively evaluated the impacts of H1‐antihistamine use in cancer patients during immunotherapy. …”
Get full text

A Mitochondria‐Related Signature in Diffuse Large B‐Cell Lymphoma: Prognosis, Immune and Therapeutic Features by Zhen‐Zhong Zhou, Jia‐Chen Lu, Song‐Bin Guo, Xiao‐Peng Tian, Hai‐Long Li, Hui Zhou, Wei‐Juan Huang

“…Distinct immune microenvironment, responses to immunotherapy and predictive drug IC50 values were found between groups. …”
Get full text

Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites by Yun Teng, Chao Luo, Xiaolan Qiu, Jingyao Mu, Mukesh K. Sriwastva, Qingbo Xu, Minmin Liu, Xin Hu, Fangyi Xu, Lifeng Zhang, Juw Won Park, Jae Yeon Hwang, Maiying Kong, Zhanxu Liu, Xiang Zhang, Raobo Xu, Jun Yan, Michael L. Merchant, Craig J. McClain, Huang-Ge Zhang

“…Here we investigate the impact of plant-derived nanoparticles (PNP) on gut microbiota and metabolites in context of cancer immunotherapy with the humanized gnotobiotic mouse model. …”
Get full text

Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma by Shang K, He Q, Xu X, Luo X, Zhao C, Liu L, Li Z, Li Y, Jin F

“…Multivariate logistic regression analysis showed that pretreatment lactate dehydrogenase (LDH) (p = 0.079) is an independent predictor of thyroid dysfunction after radiotherapy in combination with immunotherapy for LA-NPC.Conclusion: The study found that the addition of immunotherapy increases the risk and shortens the onset time of thyroid dysfunction in LA-NPC patients treated with chemoradiotherapy. …”
Get full text

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer by Guisen Yin, Xin Liu, Xiangtao Yu, Song Tan, Fen Liu

“…Patients treated with the new immune drug therapy had longer PFS than those treated with the original immunotherapy (5.0 months vs. 3.7 months, p = 0.0438). …”
Get full text

Identification of CD8+ T Cell-Related Genes: Correlations with Immune Phenotypes and Outcomes of Liver Cancer by Qi Pan, Ying Cheng, Donghua Cheng

“…Treatment outcomes for advanced liver cancer are poor. Immunotherapy is a treatment strategy that has been widely used to treat other cancers. …”
Get full text

High‐Throughput Single‐Nucleus RNA Profiling of Minimal Puncture FFPE Samples Reveals Spatiotemporal Heterogeneity of Cancer by Weiqin Jiang, Xiang Zhang, Ziye Xu, Qing Cheng, Xiaohan Li, Yuyi Zhu, Fangru Lu, Ling Dong, Linghui Zeng, Weixiang Zhong, Yongcheng Wang, Longjiang Fan, Hongyu Chen

“…Utilizing 7 puncture FFPE samples of liver metastases from 3 colorectal cancer patients pre‐ and post‐immunotherapy, the cellular developmental trajectories are reconstructed and revealed dynamic spatiotemporal heterogeneity during treatment, including insights into pseudoprogression of immunotherapy. …”
Get full text

Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma by Shunhan Yao, Meiling Deng, Xiaojing Du, Qingfeng Chen, Rongzhi Huang

“…Further, the two immune subtypes are shown to differ in immunotherapy and chemotherapy. The results would be helpful for clinical decision in osteosarcoma.…”
Get full text